Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan

REFERENCES

• United States Census Bureau (BUCEN), International Programs Center. International Data Base. Mid- year Population by Special Age Groups and Sex – Custom Region – Uzbekistan. Accessed 12 October 2012 from: http://www.census.gov/population/international/data/idb/region.php?N=%20Results%20&T=5&A=separate&RT=0&Y=2012&R=21&C=UZ
   Google Scholar
• International Consortium for Medical Abortion. Countries abortion profile: Uzbekistan. Accessed 27 August 2012 from: http://www.medicalabortionconsortium.org/country/UZ/
   Google Scholar
• Analytical and Information Centre, Ministry of Health of the Republic of Uzbekistan [Uzbekistan], State Department of Statistics, Ministry of Macroeconomics. and Statistics [Uzbekistan], and ORC Macro. 2004. Uzbekistan Health Examination Survey 2002. Calverton, Maryland, USA: Analytical and Information Centre, State Department of Statistics, and ORC Macro. Accessed 27 August 2012 from: http://measuredhs.com/pubs/pdf/FR143/00FrontMatter.pdf
   Google Scholar
• World Health Organization. Safe abortion: Technical and policy guidance for health systems, 2nd edn. Geneva: World Health Organization 2012.
   Google Scholar
• Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion: Evidence-based clinical guideline number 7. London: RCOG Press 2011.
   Google Scholar
• Faundes A. The combination of mifepristone and misoprostol for the termination of pregnancy. Int J Gynaecol Obstet 2011;115:1–4.
   PubMed Web of Science ®Google Scholar
• Akin A, Dabash R, Dilbaz B, . Increasing women's choices in medical abortion: A study of misoprostol 400 μg swallowed immediately or held sublingually following 200 mg mifepristone. Eur J Contracept Reprod Health Care 2009;14:169–75.
   PubMed Web of Science ®Google Scholar
• Ho PC. Women's perceptions on medical abortion. Contraception 2006;74:11–5.
   PubMed Web of Science ®Google Scholar
• Shannon C, Wiebe E, Jacot F, . Regimens of misoprostol with mifepristone for early medical abortion: A randomised trial. BJOG 2006;113:621–8.
   PubMed Web of Science ®Google Scholar
• Tang OS, Xu J, Cheng L, . Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002;17:1738–40.
   PubMed Web of Science ®Google Scholar
• Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracept Reprod Health Care 2000;5:171–6.
   PubMedGoogle Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002;66:247–50.
   PubMed Web of Science ®Google Scholar
• Winikoff B, Dzuba IG, Creinin MD, . Two distinct oral routes of misoprostol in mifepristone medical abortion: A randomized controlled trial. Obstet Gynecol 2008;112:1303–10.
   PubMed Web of Science ®Google Scholar
• Schaff EA, Dicenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005; 71:22–5.
   PubMed Web of Science ®Google Scholar
• Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception 2006;74:26–30.
   PubMed Web of Science ®Google Scholar
• Tran N, Jang M, Yong S. Feasibility, efficacy, safety, and acceptability of mifepristone–misoprostol for medical abortion in the Democratic People's Republic of Korea. Int J Gynaecol Obstet 2010;109:209–12.
   PubMed Web of Science ®Google Scholar
• Tang OS, Chan CCW, Ng EHY, . A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 2003;18:2315–8.
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Dow J, . A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception 2003;68:335–8.
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Flett GMM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 2005;112:1102–8.
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Huong NT, Piaggio G, . , for the WHO Research Group on Postovulatory Methods of Fertility Regulation. Misoprostol dose and route after mifepristone for early medical abortion: A randomised controlled noninferiority trial. BJOG 2010;117:1186–96.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Comendant R, Digol I, . Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days’ gestational age: A randomized controlled trial of sublingual and oral misoprostol. Contraception 2009;79:84–90.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Comendant R, Digol I, . Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days’ LMP: A randomized controlled trial. Contraception 2010;82:513–9.
   PubMed Web of Science ®Google Scholar
• Mundle S, Elul B, Anand A, . Increasing access to safe abortion services in rural India: Experiences with medical abortion in a primary health center. Contraception 2007;76:66–70.
   PubMed Web of Science ®Google Scholar
• Dahiya K, Mann S, Nanda S. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Arch Gynecol Obstet 2011;284:59–63.
   PubMed Web of Science ®Google Scholar
• Raymond EG, Shannon C, Weaver MA, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: A systematic review. Contraception 2013;87:26–37.
   PubMed Web of Science ®Google Scholar
• Bracken H, Gliozheni O, Kati K, . Mifepristone medical abortion in Albania: Results from a pilot clinical research study. Eur J Contracept Reprod Health Care 2006;11:38–46.
   PubMed Web of Science ®Google Scholar
• Akin A, Blum J, Ozalp S, . Results and lessons learned from a small medical abortion clinical study in Turkey. Contraception 2004;70:401–6.
   PubMed Web of Science ®Google Scholar
• Hajri S, Blum J, Gueddana N, . Expanding medical abortion in Tunisia: Women's experiences from a multi-site expansion study. Contraception 2004;70: 487–91.
   PubMed Web of Science ®Google Scholar
• Ngoc NTN, Nhan VQ, Blum J, . Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG 2004;111:814–9.
   PubMed Web of Science ®Google Scholar
• Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao. Eur J Contracept Reprod Health Care 2011;16:61–6.
   PubMed Web of Science ®Google Scholar
• Ministry of Health of the Republic of Moldova. Order No. 647 (21 September 2010). Ministry of Health of the Republic of Moldova. Order No. 482 (14 June 2011).
   Google Scholar
• Winikoff B, Dzuba IG, Chong E, . Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012;120:1070–6.
   PubMed Web of Science ®Google Scholar